Amgen Inc.

Xencor, Inc.

Jennitte LeAnn Stevens

John R Desjarlais

Mark E Daris

Yang Li

Matthew J Bernett

Ian Nevin Foltz

Chadwick Terence King

Gregory L Moore

Rumana Rashid

Seung Yup Chu

Gunasekaran Kannan

Shaw-Fen Sylvia Hu

Junming Yie

Randal Robert Ketchem

Umesh Muchhal

Neeraj Jagdish Agrawal

Kevin Graham

Mercedesz Balazs

Zhe Huang

Greg Flynn

Szilan Fodor

Jason Charles O'Neill

Christopher Murawsky

Benjamin M Alba

Olivier Nolan-Stevaux

Jason C O'neill

Huanying Ge

Cong Li

Chi-Ming Kevin Li

Vishnu Chintalgattu

Taeweon Lee

Noelia Blanco Talavan

Kristine M Daris

The invention generally relates to anti-sclerostin antibodies having C-terminal modifications, and compositions comprising such antibodies.

C-terminal anti-sclerostin antibody variants

The disclosure provides novel antigen-binding proteins that bind STEAP1 and methods of use.

Anti-STEAP1 antigen-binding protein

C-terminal antibody variants

The present invention provides compositions and methods relating to or derived from antigen binding proteins capable of inducing &#x3b2;-Klotho, and or FGF21-like mediated signaling. In embodiments, the antigen binding proteins specifically bind to a complex comprising &#x3b2;-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c.

Antigen binding proteins that bind to a complex comprising &#x3b2;-Klotho and an FGF receptor

The application concerns tissue inhibitor of metalloproteinase 3 (TIMP-3) muteins, variants and derivatives, nucleic acids encoding them, and methods of making and using them; in particular, muteins of TIMP-3 with specific amino acid substitutions in order to introduce N-linked glycosylation sites.

Variants of tissue inhibitor or metalloprotienase type three (TIMP-3), compositions and methods

Disclosed are a recombinant expression vector and a host cell that contains the vector.

Promoter and regulatory elements for improved expression of heterologous genes in host cells

The present invention provides compositions and methods relating to or derived from antigen binding proteins capable of inducing B-Klotho, and or FGF21-like mediated signaling.

Human antigen binding proteins that bind to a complex comprising &#x3b2;-Klotho and an FGF receptor

Growing community of inventors

Thousand Oaks, CA, United States of America

Jennitte LeAnn Stevens